CRBU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where CRBU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on CRBU as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for CRBU just turned positive on October 22, 2026. Looking at past instances where CRBU's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
Following a +7.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRBU advanced for three days, in 199 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRBU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CRBU entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.582) is normal, around the industry mean (3.043). P/E Ratio (-0.493) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (11.641) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CRBU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRBU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for GHRS just turned positive on October 23, 2026. Looking at past instances where GHRS's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where GHRS advanced for three days, in 256 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
GHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GHRS as a result. In 89 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
GHRS moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for GHRS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.450) is normal, around the industry mean (3.043). P/E Ratio (-18.253) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. GHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| CRBU | GHRS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Advances ODDS (%) | 3 days ago 79% | 5 days ago 89% |
| Declines ODDS (%) | 11 days ago 88% | 2 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 85% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRBU’s FA Score shows that 1 FA rating(s) are green while GHRS’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRBU’s TA Score shows that 5 TA indicator(s) are bullish while GHRS’s TA Score has 5 bullish TA indicator(s).
CRBU (@Biotechnology) experienced а +13.39% price change this week, while GHRS (@Biotechnology) price change was -0.44% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
CRBU is expected to report earnings on Nov 11, 2026.
GHRS is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| USDX | 25.63 | -0.01 | -0.04% |
| SGI Enhanced Core ETF (USDX) | |||
| FLHY | 23.42 | -0.02 | -0.11% |
| Franklin High Yield Corporate ETF (FLHY) | |||
| FTCE | 27.45 | -0.07 | -0.26% |
| First Trust New Constructs Core Earnings Leaders ETF (FTCE) | |||
| EEE | 22.36 | -0.07 | -0.33% |
| CYBER HORNET S&P 500 and Ethereum 75/25 Strategy ETF (EEE) | |||
| DAMD | 11.80 | -0.44 | -3.59% |
| Defiance Daily Target 2X Short AMD ETF (DAMD) | |||
A.I.dvisor indicates that over the last year, CRBU has been loosely correlated with AXON. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBU jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To CRBU | 1D Price Change % | ||
|---|---|---|---|---|
| CRBU | 100% | -4.86% | ||
| AXON - CRBU | 50% Loosely correlated | +1.39% | ||
| CRSP - CRBU | 43% Loosely correlated | -1.20% | ||
| EDIT - CRBU | 41% Loosely correlated | -3.61% | ||
| SLDB - CRBU | 40% Loosely correlated | -4.36% | ||
| LCTX - CRBU | 40% Loosely correlated | +1.52% | ||
More | ||||
A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with STTK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then STTK could also see price increases.
| Ticker / NAME | Correlation To GHRS | 1D Price Change % | ||
|---|---|---|---|---|
| GHRS | 100% | -2.32% | ||
| STTK - GHRS | 43% Loosely correlated | -1.96% | ||
| FDMT - GHRS | 39% Loosely correlated | -8.86% | ||
| IMRX - GHRS | 38% Loosely correlated | -2.10% | ||
| CABA - GHRS | 38% Loosely correlated | -3.29% | ||
| CGEN - GHRS | 37% Loosely correlated | -1.02% | ||
More | ||||